Clinical Trial Update: Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib in combination with capecitabine for hepatocellular carcinoma was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-07-17